SHOC2 Antibody [H23M19]

Catalog No.: F5330

    Application: Reactivity:
    • Lane 1: T47D, Lane 2: HCT116, Lane 3: HT29, Lane 4: C6
    1/

    当該製品は品切れ状态で、ごメールアドレスを教えていただければ、在庫があると、メールで顧客様に伝えます。

    代表番号: 045-509-1970|電子メール:sales@selleck.co.jp

    使用情報

    Dilution
    1:1000
    Application
    WB
    Source
    Rabbit Monoclonal Antibody
    Reactivity
    Human, Mouse, Rat, Monkey
    Storage Buffer
    PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3
    Storage (from the date of receipt)
    -20°C (avoid freeze-thaw cycles), 2 years
    Predicted MW
    64 kDa

    Datasheet & SDS

    生物学的記述

    Specificity
    SHOC2 Antibody [H23M19] detects endogenous levels of total SHOC2 protein.
    Clone
    H23M19
    Synonym(s)
    Leucine-rich repeat protein SHOC-2; Ras-binding protein Sur-8 homolog; SHOC2
    Background
    SHOC2 is a leucine‑rich repeat (LRR)‑containing scaffold protein that positively regulates RAS‑MAPK signaling and intersects with the PI3K/Akt axis, functioning as a modular platform that coordinates the assembly and dynamics of specific signaling complexes. SHOC2 folds into a concave LRR‑rich domain that mediates multiple protein–protein interactions, enabling its recruitment to activated RAS‑GTP and to the catalytic subunit of protein phosphatase 1 (PP1), while its N‑terminal region participates in competitive membrane association and regulatory switches. SHOC2 forms a ternary complex with a regulatory PP1 subunit and the GTP‑bound small GTPase M‑RAS, and this complex serves as a dedicated accelerator of RAF–MEK–ERK signaling, promoting RAF dimerization and MEK/ERK phosphorylation downstream of receptor‑tyrosine‑kinase‑driven growth‑factor inputs. SHOC2 engages the p110α catalytic subunit of PI3K, thereby linking RAS‑MAPK activation to PI3K/Akt stimulation and broadening the range of downstream transcriptional and metabolic outputs that depend on coordinated ERK and Akt signaling. This dual engagement of ERK and PI3K/Akt pathways underlies SHOC2’s role in promoting cell motility, cytoskeletal remodeling, and invasive behavior in epithelial and cancer cell contexts, where its expression supports processes that increase migratory capacity and metastatic potential. A germline SHOC2 mutation that introduces an N‑terminal myristoylation motif causes aberrant constitutive membrane targeting of the protein, leading to sustained, growth‑factor‑independent enhancement of RAF–ERK signaling and underpinning the hyperactive RAS–MAPK phenotype in Noonan‑like syndrome with loose anagen hair.
    References

    技術サポート

    ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

    Handling Instructions

    他に質問がある場合は、お気軽にお問い合わせください。

    * 必須

    大学・企業名を記入してください
    名前を記入してください
    電子メール・アドレスを記入してください 有効なメールアドレスを入力してください
    お問い合わせ内容をご入力ください